Completed OBSERVATIONAL NCT07126132
Hpx•apoB Product as a Biomarker for Coronary Artery Disease
The Hemopexin-Apolipoprotein B Product: A Novel Biomarker Integrating Oxidative Stress and Lipid Metabolism for Coronary Artery Disease Risk Stratification
Sponsor: Shiyan City Renmin Hospital
Conditions
Coronary Artery Disease
Interventions
Coronary Angiography Hpx•apoB Product Measurement
Updated 1 time since 2025 Last updated: Aug 14, 2025 Started: Jan 1, 2019 Primary completion: Dec 31, 2023 Completion: Dec 31, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A observational or N/A phase clinical study on Coronary Artery Disease, this trial is completed. The trial is conducted by Shiyan City Renmin Hospital and has accumulated 1 data snapshot since 2019. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
1 version recorded Completed
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Shiyan City Renmin Hospital
Data source: Shiyan City Renmin Hospital
For direct contact, visit the study record on ClinicalTrials.gov .